
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Novotech, an Asia-Pacific-based CRO, has acquired Australasian specialist CRO Clinical Network Services (CNS) as part of a mission in hopes to expand services to biopharma for early phase product development and clinical research through to later phase regional and global trials.
Read the full release






